Argentina's Clearer Patent System to Attract More Investment, Says Bayer Executive

Philip Glaser, President of Bayer's Pharma ConoSur, highlights a pivotal moment for Argentina's pharmaceutical sector, emphasizing how a modernized patent system is unlocking new avenues for investment and innovation. Bayer, a global giant with deep roots in Argentina, sees the recent resolution on patentability as a landmark achievement, aligning the country with international standards and fostering a more secure environment for intellectual property.

This regulatory clarity is crucial. For years, inconsistencies in patent and intellectual property laws acted as a significant deterrent for multinational corporations like Bayer. Glaser, speaking from Mexico City after the company's Latam Media Day, expressed optimism that this change will not only encourage greater local production but also stimulate vital research and development within Argentina. The country's existing infrastructure, including its status as home to South America's largest tablet factory, provides a strong foundation for this anticipated growth.

“

now generates the possibility of bringing more investments to Argentina in terms of local production and research because patents will be respected.

Bayer's pharmaceutical division in the Southern Cone, which includes Argentina, Uruguay, Paraguay, Peru, and Bolivia, saw a remarkable 27% growth in 2025. Argentina alone accounted for a substantial 77% of the division's sales in the region, underscoring its strategic importance. Growth drivers include treatments for serious conditions like prostate cancer, diabetic macular edema, and pulmonary hypertension, as well as female health products. Argentina's role as a key clinical research hub further solidifies its position within Bayer's global operations.

From an Argentinian perspective, this development signifies more than just increased investment; it represents a strengthening of the national pharmaceutical industry and a commitment to scientific advancement. The alignment with international patent standards, a long-standing demand from trading partners like the United States, demonstrates Argentina's willingness to adapt and integrate into the global economy. This move is seen not just as a concession, but as a strategic step towards becoming a more competitive and attractive destination for high-value industries, fostering both economic growth and technological progress.

“

as an executive member of the Argentine Chamber of Medicinal Specialties (Caeme), we celebrate Joint Resolution 1/2026 which modernizes the pharmaceutical patent regime, strengthening legal certainty and predictability in intellectual property matters.